Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presented mixed signals: EPS beat expectations, but guidance remains negative. Regulatory challenges and competitive pressures pose risks. The Q&A highlighted demand for trials but also revealed management's evasiveness on critical details, which might concern investors. Although EPS improved, the lack of clear shareholder return strategy and ongoing challenges suggest a neutral stock movement.
Key Financial Performance
Earnings Per Share (EPS) Reported EPS is $-0.16, which is an improvement from expectations of $-0.18.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Earnings Performance: Gossamer Bio, Inc. reported an earnings per share (EPS) of $-0.16, surpassing expectations of $-0.18.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Performance: Gossamer Bio, Inc. reported an EPS of $-0.16, beating expectations of $-0.18.
Regulatory Challenges: Caryn Peterson discussed ongoing regulatory challenges that may impact the timeline for product approvals.
Competitive Pressures: Faheem Hasnain highlighted increasing competitive pressures in the biotech sector that could affect market share.
Supply Chain Issues: Bryan Giraudo mentioned potential supply chain disruptions that could impact production and distribution.
Economic Factors: The team acknowledged broader economic factors that may influence funding and investment opportunities.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Earnings Per Share (EPS) Guidance: The company expects EPS to improve to a range of $-0.12 to $-0.14 for Q2 2025.
Revenue Expectations: Projected revenue for Q2 2025 is anticipated to be between $5 million and $7 million.
Capital Expenditures (CapEx): CapEx for the upcoming quarter is estimated to be around $2 million.
Long-term Strategic Initiatives: Gossamer Bio is focusing on advancing its pipeline of therapeutics, particularly in immunology and oncology, with several key clinical trials expected to initiate in the next 12 months.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:With 343 patients enrolled in PROSERA to date, have you considered stopping enrollment there in order to be able to still report data this year?
A:It really relates to the fact that there’s been such incredible demand to study, Joe. And obviously, as we started to signal that we were nearing the end of enrollment that demand got even bigger. And it’s really important that we honor the commitment we have to patients and to their physicians to ensure that — we have worked alongside of all of these physicians, continue to do so into the future.
Q:Could we delve some more into baseline characteristics in PROSERA? Since the TORREY trial enrolled patients primarily from North America, whereas PROSERA will be more global, I was wondering if we could get your thoughts on how this factor could influence the results.
A:PROSERA has a much broader global footprint in the context of the sites that we’ve enrolled. As an example, there is a significant portion of patients that will come out of places like Latin America, South America, Eastern European countries and Asia Pacific.
Q:With baseline in PROSERA now in hand, have powering assumptions changed at all?
A:The study intentionally was designed to enroll this population, so in anticipation of the treatment effect that we would observe, which is complementary to the sample size and the expected power.
Q:Did you look at baseline PVR in the PROSERA study?
A:We did have a PVR entry criteria of 400 or greater. We did not mandate to have a PVR as an endpoint.
Q:Are you planning to give us another cut of the baseline and maybe a little bit additional information?
A:We don’t expect that to materially change given just the number of patients that we’ve been able to evaluate baselines on.
Q:Can you just remind us what Chiesi-related milestones are sort of baked into your cash runway guidance?
A:Our cash flow does not have any of the big milestones that we would expect on regulatory milestones.
Q:Can you share or do you plan to share with the final baseline just what baseline sotatercept usage is?
A:We had expectations that we would probably have about 10% of the study or roughly 35 patients on background sotatercept.
Q:Can you just talk about the population you’re aiming to enroll in SERANATA for PH-ILD?
A:We have some similarities, but clearly some differences, and I can just highlight some of those differences.
Q:What are the implications for the product profile if you’re able to demonstrate a beneficial impact on underlying interstitial lung disease?
A:Assuming that we have positive results, not only would it be differentiating for us, but we would obviously have a discussion with regulators about potential mentioning of it or positioning of it in the product label.
Q:Can you maybe compare the commercial opportunity for this drug in KH versus PH-ILD?
A:If you look at PAH, there’s about 50,000 patients in the U.S. If you look at the current pricing of the newer therapies, obviously we haven’t presented anything publicly.
Q:Review of Unclear Management Responses
A:Management appeared to avoid giving a direct answer regarding the specific baseline characteristics of patients who discontinued Sotatercept and how that might impact the study results. Additionally, there was a lack of clarity on the specific regulatory thresholds the FDA is looking for regarding six-minute walk improvement.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
CEO President
Co Founder
Founder CEO
President Chairman
GOSS Transcript
Gossamer Bio, Inc. (GOSS) Q1 2026 Earnings Call Transcript
Unknown5-18
The earnings call summary lacks explicit financial performance details, with no mention of revenue, margins, or cash flow. Regulatory and commercialization plans for seralutinib suggest potential growth, but regulatory and financial risks introduce uncertainties. The absence of clear shareholder return plans and unclear management responses in the Q&A section further support a neutral outlook. Without a market cap, the stock's reaction is uncertain, leading to a neutral sentiment rating.
Gossamer Bio, Inc. (NASDAQ:GOSS) Q1 2025 Earnings Call Transcript
Unknown5-17
The earnings call presented mixed signals: EPS beat expectations, but guidance remains negative. Regulatory challenges and competitive pressures pose risks. The Q&A highlighted demand for trials but also revealed management's evasiveness on critical details, which might concern investors. Although EPS improved, the lack of clear shareholder return strategy and ongoing challenges suggest a neutral stock movement.
Earnings call transcript: Gossamer Bio exceeds Q1 2025 revenue forecasts
Unknown5-15
The earnings call showed improved net loss figures and cost management, but the Q&A revealed some uncertainties, particularly around enrollment and regulatory milestones. While management expressed confidence in their safety profile and global trial expansion, they avoided direct answers on key metrics, raising concerns. The lack of clear guidance and the decision to push data into 2026 may temper investor enthusiasm, resulting in a neutral stock price reaction.
Gossamer Bio, Inc. (GOSS) Q1 2025 Earnings Conference Call Transcript
Unknown5-15
The earnings call reveals mixed signals. Financial performance shows some improvement, with increased revenue and reduced net loss. However, high R&D expenses and the critical dependency on clinical trial outcomes pose risks. The Q&A session highlights management's confidence in trial safety and market potential but also reveals uncertainties in patient enrollment and regulatory milestones. Overall, the sentiment is balanced with positive and negative elements, resulting in a neutral rating for the stock's short-term movement.
GOSS Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
